UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2575858 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2575858 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2575858 (State or other jurisdiction ...

First, PLD causes immunogenic cell death of ovarian cancer cells and was shown to enhance antitumor activity when combined with 154 in preclinical studies. Second, PLD is a standard-of-care in the platinum-resistant setting and is well-known that patients treated with PLD have an objective response rate in the range of 10% to 12% from multiple Phase 3 clinical trials. Thus, this was a mechanistically driven combination strategy where we do not expect difficulty determining the contribution of 154 and the re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2575858 (State or other jurisdiction of ( ...

Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Conor Richardson - Senior Director of Finance and Investor Relations Taylor Schreiber - Chief Executive Officer Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen Gil Blum - Needham & Company Carly Kenselaar - Citi Kaveri Pohlman - BTIG Zhiqiang Shu - Berenberg Operator Good afternoon, everyone, and welcome to Shattuck La ...

| --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | Corporate Overview NASDAQ: STTK March 15, 2022 | | | | | | | | | | | SHATTUCK PIONEERING NOVEL BI-FUNCTIONAL FUSION PROTEINS EXPANDING THE BOUNDARIES OF BIOLOGIC MEDICINES Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are b ...

| --- | --- | --- | --- | --- | --- | |--------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Corporate Overview NASDAQ: STTK January 10, 2021 | | | | | | | | | | | | | SHATTUCK PIONEERING NOVEL BI-FUNCTIONAL FUSION PROTEINS EXPANDING THE BOUNDARIES OF BIOLOGIC MEDICINES Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and ...

Shattuck Labs, Inc. (NASDAQ:STTK) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Conor Richardson – Senior Director of Finance and Investor Relations Taylor Schreiber – Chief Executive Officer Lini Pandite – Chief Medical Officer Andrew Neill – Chief Financial Officer Conference Call Participants Ernie Rodriguez – Cowen Jonathan Miller – Evercore ISI Gil Blum – Needham Zhiqiang Shu – Berenberg Operator Good afternoon, everyone, and welcome to Shattuck Labs Second Quarter Fi ...

| --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | Corporate Overview NASDAQ: STTK August 11, 2021 | | | | | | | | | | | | | | | SHATTUCK PIONEERING NOVEL BI-FUNCTIONAL FUSION PROTEINS EXPANDING THE BOUNDARIES OF BIOLOGIC MEDICINES Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to sub ...